Form 4: Guardant Health CCO's Routine Stock Transactions

Guardant Health's Chief Commercial Officer, Chris Freeman, reported routine acquisitions of common stock through restricted stock unit vesting and subsequent tax-related dispositions.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported transactions on October 1, 2025.
• Acquired a total of 13,550 shares of common stock through the vesting of restricted stock units (RSUs).
• Disposed of 5,740 shares of common stock at a price of $62.65 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Freeman directly beneficially owns 57,439 shares of Guardant Health common stock.
• Freeman also holds 34,593 unvested Restricted Stock Units.
• The RSU awards were granted on November 7, 2022, December 13, 2023, and November 8, 2024, with varying vesting schedules.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax withholding), which are neither significantly positive nor negative for the company's operational or financial performance.

Positives

• Chris Freeman acquired 13,550 shares of common stock through the vesting of restricted stock units, increasing his direct ownership in the company.
• The vesting of RSUs represents a realization of compensation for the Chief Commercial Officer.

Negatives

• 5,740 shares of common stock were disposed of to cover tax withholding obligations, reducing the net shares acquired.

Future Outlook

The remaining 75% of the restricted stock unit award granted on November 7, 2022, will vest in equal quarterly installments over the subsequent three-year period. The remaining 67% of the restricted stock unit award granted on December 13, 2023, will vest in equal quarterly installments over the subsequent two-year period. The remaining 67% of the restricted stock unit award granted on November 8, 2024, will vest in equal quarterly installments over the subsequent two-year period.

Industry Context

This filing represents a routine compensation event for an executive, common across publicly traded companies, and does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor, routine dilution from RSU vesting, but also indicates continued alignment of executive interests with shareholder value through equity ownership.
• Employees: Reflects standard executive compensation practices, potentially influencing employee perception of equity incentives.

Next Steps

• Remaining portions of the RSU award granted on November 7, 2022, will vest in equal quarterly installments over the next three years.
• Remaining portions of the RSU award granted on December 13, 2023, will vest in equal quarterly installments over the next two years.
• Remaining portions of the RSU award granted on November 8, 2024, will vest in equal quarterly installments over the next two years.

Key Dates

Keywords

Guardant Health, GH, Chris Freeman, Chief Commercial Officer, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Compensation, Tax Withholding, Beneficial Ownership